Literature DB >> 11405645

Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.

S K Sharma1, R M Jones, T G Metzger, D M Ferguson, P S Portoghese.   

Abstract

The importance of the indole scaffold of GNTI 3 in directing its address (5'-guanidinium group) to associate with the Glu297 residue of the kappa-opioid receptor was investigated by the synthesis and biological evaluation of its 4'- (4a), 6'- (4b), and 7'- (4c) regioisomers. The finding that only the 5'-regioisomer (GNTI) possessed potent kappa-opioid antagonist activity and high affinity at kappa-receptors illustrates the importance of the 5'-position in orienting the guanidinium group to the proper recognition locus (Glu 297) for potent kappa-antagonist activity. The discovery that the 6'-regioisomer of GNTI was a potent kappa-agonist, together with the results of site-directed mutagenesis studies that are consistent with association between the 6'-guanidinium group and Glu297, suggest that the transition from an inactive to an active state of the kappa-receptor involves a conformational change of TM6. We propose that association of the 6'-guanidinium group of 4b with Glu297 promotes axial rotational motion of transmembrane helix VI which leads to receptor activation via a conformational change of inner loop 3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405645     DOI: 10.1021/jm010095v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Authors:  Kelly A Berg; Matthew P Rowan; Achla Gupta; Teresa A Sanchez; Michelle Silva; Ivone Gomes; Blaine A McGuire; Philip S Portoghese; Kenneth M Hargreaves; Lakshmi A Devi; William P Clarke
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

2.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 3.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

5.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Authors:  Maria Waldhoer; Jamie Fong; Robert M Jones; Mary M Lunzer; Shiv K Sharma; Evi Kostenis; Philip S Portoghese; Jennifer L Whistler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

6.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

7.  Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.

Authors:  V Blair Journigan; Christophe Mésangeau; Neha Vyas; Shainnel O Eans; Stephen J Cutler; Jay P McLaughlin; Catherine Mollereau; Christopher R McCurdy
Journal:  J Med Chem       Date:  2014-10-21       Impact factor: 7.446

8.  A novel method for analyzing extremely biased agonism at G protein-coupled receptors.

Authors:  Edward L Stahl; Lei Zhou; Frederick J Ehlert; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-02-13       Impact factor: 4.436

9.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

10.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.